Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Epizyme Inc (EPZM)

Epizyme Inc (EPZM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,345,598
  • Shares Outstanding, K 101,478
  • Annual Sales, $ 23,800 K
  • Annual Income, $ -170,300 K
  • 60-Month Beta 1.92
  • Price/Sales 55.94
  • Price/Cash Flow N/A
  • Price/Book 5.18

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.60
  • Number of Estimates 6
  • High Estimate -0.53
  • Low Estimate -0.63
  • Prior Year -0.40
  • Growth Rate Est. (year over year) -50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.81 +12.28%
on 09/11/20
13.59 -2.43%
on 09/18/20
+1.13 (+9.32%)
since 08/18/20
3-Month
11.81 +12.28%
on 09/11/20
19.92 -33.43%
on 06/19/20
-7.20 (-35.19%)
since 06/18/20
52-Week
9.73 +36.28%
on 10/09/19
27.82 -52.34%
on 01/21/20
+1.52 (+12.95%)
since 09/18/19

Most Recent Stories

More News
Epizyme Inc Shares Down 16.2% Since SmarTrend's Sell Call (EPZM)

SmarTrend identified a Downtrend for Epizyme Inc (NASDAQ:EPZM) on July 2nd, 2020 at $15.81. In approximately 2 months, Epizyme Inc has returned 16.23% as of today's recent price of $13.24.

EPZM : 13.26 (+1.07%)
Epizyme to Participate in Morgan Stanley 18th Annual Global Healthcare Conference

Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that Robert Bazemore, president and chief...

EPZM : 13.26 (+1.07%)
First Week of October 16th Options Trading For Epizyme (EPZM)

Investors in Epizyme Inc. saw new options begin trading this week, for the October 16th expiration.

EPZM : 13.26 (+1.07%)
Epizyme's (EPZM) Q2 Earnings and Revenues Miss Estimates

Epizyme (EPZM) reports a wider-than-expected loss and misses sales estimates in the second quarter of 2020.

PFE : 36.63 (-0.52%)
MRK : 85.81 (+0.20%)
NVS : 90.94 (-0.03%)
EPZM : 13.26 (+1.07%)
Epizyme (EPZM) Reports Q2 Loss, Misses Revenue Estimates

Epizyme (EPZM) delivered earnings and revenue surprises of -3.57% and -47.12%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

EPZM : 13.26 (+1.07%)
Epizyme: 2Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Epizyme Inc. (EPZM) on Tuesday reported a loss of $58.5 million in its second quarter.

EPZM : 13.26 (+1.07%)
Epizyme Reports Business Progress and Second Quarter 2020 Financial Results

--Conference Call to be Held Today, August 4 at 8:30 a.m. ET

EPZM : 13.26 (+1.07%)
Watch for Epizyme Inc to Potentially Rebound After Falling 9.51% Yesterday

Epizyme Inc (NASDAQ:EPZM) traded in a range yesterday that spanned from a low of $17.91 to a high of $19.92. Yesterday, the shares fell 9.5%, which took the trading range below the 3-day low of $18.03...

EPZM : 13.26 (+1.07%)
Roche receives FDA approval for cobas EZH2 Mutation Test as a companion diagnostic for patients with follicular lymphoma

, /PRNewswire/ -- Roche (SIX: RO, ROG;OTCQX: RHHBF) today announced U.S. Food and Drug Administration (FDA) approval of the cobas EZH2 Mutation Test as a companion diagnostic for TAZVERIK(tazemetostat),...

EPZM : 13.26 (+1.07%)
Epizyme Gets FDA Nod for Tazverik sNDA in Follicular Lymphoma

The FDA grants approval to Epizyme's (EPZM) sNDA for lead drug,Tazverik, for two distinct follicular lymphoma indications.

RHHBY : 46.8400 (+1.04%)
GSK : 39.26 (-0.53%)
EPZM : 13.26 (+1.07%)
AKCA : 18.15 (+0.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade EPZM with:

Business Summary

Epizyme, Inc. is a biopharmaceutical company. It engages in the discovery, development, planning, and commercialization of therapeutics for cancers. Epizyme, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

2nd Resistance Point 13.89
1st Resistance Point 13.58
Last Price 13.26
1st Support Level 12.96
2nd Support Level 12.65

See More

52-Week High 27.82
Fibonacci 61.8% 20.91
Fibonacci 50% 18.77
Fibonacci 38.2% 16.64
Last Price 13.26
52-Week Low 9.73

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar